TearSolutions is a clinical-stage biotechnology company spun out of the University of Virginia that is advancing topical treatments for dry eye. The drug, Lacripep, is a synthetic fragment of the human tear protein Lacritin discovered and developed with National Eye Institute funding. Topical Lacripep is a breakthrough opportunity that in preclinical studies eliminates corneal staining and independently promotes basal tearing without irritation for hours by natural physiological processes.